Canada markets closed

Atai Life Sciences N.V. (ATAI)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
3.3100+0.0600 (+1.85%)
At close: 04:00PM EDT
3.4800 +0.17 (+5.14%)
After hours: 07:37PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close3.2500
Open3.1400
Bid3.1600 x 1200
Ask3.5200 x 4000
Day's Range3.1400 - 3.4200
52 Week Range2.9500 - 17.8100
Volume525,702
Avg. Volume787,766
Market Cap549.046M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.3990
Earnings DateAug 15, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est23.96
  • GlobeNewswire

    atai Life Sciences Announces Initiation of Phase 1 Trial for its MDMA Derivative, EMP-01

    - atai’s wholly owned subsidiary, EmpathBio, has received Medsafe central regulatory and The Health and Disability Ethics Committees (HDEC) ethics approvals to initiate a Phase 1 trial to assess the safety and tolerability of orally administered EMP-01 in 32 healthy volunteers - EMP-01 is a 3,4-methylenedioxy-methamphetamine (MDMA) derivative under development for the treatment of post-traumatic stress disorder (PTSD) and other indications NEW YORK and BERLIN, Sept. 27, 2022 (GLOBE NEWSWIRE) --

  • GlobeNewswire

    atai Life Sciences to Participate in September Investor Events

    NEW YORK and BERLIN, Sept. 07, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following investor conferences in September: Citi’s 17th Annual BioPharma Conference in BostonFormat: Industry PanelDate and Time: Wednesday, September 7th, 10:30 a.m. ET – 11:15 a.m. ETConference Link: URL H.C. Wainwright’s 24th Annual Global Investment Conference

  • GlobeNewswire

    atai Life Sciences Reports Second Quarter 2022 Financial Results & Business Update

    - Added an anticipated additional year of runway into 2025 through securing non-dilutive debt facility from Hercules combined with execution of cost optimizations by prioritizing atai’s development programs with anticipated meaningful near-term clinical value inflections- Key achieved R&D milestones include completion of the clinical phase of the Drug-Drug-Interaction (DDI) study of PCN-101, database lock for the GRX-917 Phase 1 trial, completion of SAD portion of ongoing KUR-101 Phase 1 trial,